What Happened
India’s semaglutide patent has expired, triggering a competitive push among local manufacturers that industry observers describe as a price war. The development comes as demand for GLP‑1 receptor agonists used for weight loss has grown, driven by patients seeking medical options alongside lifestyle changes.
Individuals already using weekly semaglutide injections say the medication can deliver significant short‑term weight loss. One 29‑year‑old interior designer, who began treatment in January, reported losing about 6kg (13lbs) in two months while also changing her diet and exercise routine. Before treatment she weighed 85kg at 1.65 metres and was classed as obese.
Background
Semaglutide belongs to a class of drugs originally developed for diabetes that are now widely prescribed for weight management. The injections are typically administered weekly and have been credited with helping patients reduce weight when used alongside lifestyle measures.
With the patent lapse in India, multiple manufacturers are moving to market competing versions. The anticipated increase in suppliers is expected to put downward pressure on prices within India’s domestic market and expand availability for patients who previously found branded products unaffordable.
What This Means
For patients in India, the entry of generics could improve access to a medication many consider effective for weight loss. Lower prices may allow more people to combine medical treatment with diet and exercise, potentially changing how obesity is managed at scale.
There are also broader regional implications. An expanded generic supply from India could influence availability and pricing in other markets, including parts of Latin America, though the specifics of exports, regulatory approvals and distribution will determine actual impact. Health systems and regulators in Panama and neighbouring countries may face new decisions about approvals, coverage and guidance on clinical use as cheaper options become available globally.
Clinicians and public health experts emphasize that medication should complement, not replace, lifestyle changes and that treatment decisions require medical oversight. As competition unfolds, authorities will be watching for effects on safety monitoring, prescribing practices and equitable access.